CN1737007A - Gastrodine derivative, its preparation method, pharmaceutical composition and uses - Google Patents
Gastrodine derivative, its preparation method, pharmaceutical composition and uses Download PDFInfo
- Publication number
- CN1737007A CN1737007A CN 200410056936 CN200410056936A CN1737007A CN 1737007 A CN1737007 A CN 1737007A CN 200410056936 CN200410056936 CN 200410056936 CN 200410056936 A CN200410056936 A CN 200410056936A CN 1737007 A CN1737007 A CN 1737007A
- Authority
- CN
- China
- Prior art keywords
- methyl
- phenylpyran
- acetyl
- glucoside
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PUQSUZTXKPLAPR-UJPOAAIJSA-N Gastrodin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(CO)C=C1 PUQSUZTXKPLAPR-UJPOAAIJSA-N 0.000 title claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 5
- 238000002360 preparation method Methods 0.000 title claims description 14
- 239000003814 drug Substances 0.000 claims abstract description 8
- -1 phenyl aldehyde Chemical class 0.000 claims description 70
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000007924 injection Substances 0.000 claims description 14
- 238000002347 injection Methods 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 3
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims 2
- 208000019736 Cranial nerve disease Diseases 0.000 claims 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 claims 1
- 229940045511 barium chloride Drugs 0.000 claims 1
- 229910001626 barium chloride Inorganic materials 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 125000003147 glycosyl group Chemical group 0.000 claims 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 230000035484 reaction time Effects 0.000 claims 1
- 235000005074 zinc chloride Nutrition 0.000 claims 1
- 239000011592 zinc chloride Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 13
- NEZJDVYDSZTRFS-RMPHRYRLSA-N Phenyl beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1 NEZJDVYDSZTRFS-RMPHRYRLSA-N 0.000 abstract description 2
- 229930182478 glucoside Natural products 0.000 description 60
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 206010010904 Convulsion Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 230000036461 convulsion Effects 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229960003226 nikethamide Drugs 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 208000012886 Vertigo Diseases 0.000 description 4
- 239000002269 analeptic agent Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 208000004296 neuralgia Diseases 0.000 description 4
- NCYVXEGFNDZQCU-UHFFFAOYSA-N nikethamide Chemical compound CCN(CC)C(=O)C1=CC=CN=C1 NCYVXEGFNDZQCU-UHFFFAOYSA-N 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 230000001624 sedative effect Effects 0.000 description 4
- 239000008354 sodium chloride injection Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 231100000889 vertigo Toxicity 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000001773 anti-convulsant effect Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 206010042772 syncope Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000005915 GABA Receptors Human genes 0.000 description 2
- 108010005551 GABA Receptors Proteins 0.000 description 2
- 241000305491 Gastrodia elata Species 0.000 description 2
- 229930183217 Genin Natural products 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 208000007443 Neurasthenia Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 208000008765 Sciatica Diseases 0.000 description 2
- 206010061373 Sudden Hearing Loss Diseases 0.000 description 2
- 208000001407 Vascular Headaches Diseases 0.000 description 2
- 201000006559 Vertebrobasilar insufficiency Diseases 0.000 description 2
- 230000002082 anti-convulsion Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 201000010861 basilar artery insufficiency Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000010907 mechanical stirring Methods 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- 201000000200 vestibular neuronitis Diseases 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- YEKPNMQQSPHKBP-UHFFFAOYSA-N 2-methyl-6-nitrobenzoic anhydride Chemical compound CC1=CC=CC([N+]([O-])=O)=C1C(=O)OC(=O)C1=C(C)C=CC=C1[N+]([O-])=O YEKPNMQQSPHKBP-UHFFFAOYSA-N 0.000 description 1
- PUQSUZTXKPLAPR-KSSYENDESA-N 4-(beta-D-Glucopyranosyloxy) benzyl alcohol Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-KSSYENDESA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010013980 Dyssomnias Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005262 decarbonization Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930193974 gastrodin Natural products 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- PUQSUZTXKPLAPR-NZEXEKPDSA-N helicidol Natural products O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-NZEXEKPDSA-N 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229930182487 phenolic glycoside Natural products 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- JWBPVFVNISJVEM-UHFFFAOYSA-M sodium caffeine benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2C JWBPVFVNISJVEM-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a gastrodine derivative, its preparing process, pharmaceutical compositions containing it and the use as medicament. More specifically, the derivative has an English name of 4-(acetoxymethyl)phenylglucoside.
Description
Invention field
The present invention relates to gastrodin derivative, its preparation method contains its pharmaceutical composition and as the application of medicine.Specifically, gastrodin derivative of the present invention is 4-(acetyl-o-methyl) phenylpyran glucoside, and is English by name: 4-(Acetoxymethyl) phenylglucoside.
Background technology
Gastrodine is a main active substances in Chinese traditional rare medicinal herbs orchid rhizoma Gastrodiae, belong to the phenolic glycoside compounds, have calmness, sleep peacefully, the analgesic effect, be used for dizzy: Meniere, medicine toxic vertigo, traumatic vertigo, sudden deafness, vestibular neuronitis, vertebro-basilar artery insufficiency etc.; Neurodynia: trigeminal neuralgia, sciatica, neuralgia of greater occipital nerve etc.; Headache: vascular headache, migraine, neurasthenia and the god syndrome etc. that declines; Also can be used for diseases such as assisting therapy epilepsy.The structure of Gastrodine is:
Said structure shows, in the Gastrodine in glycosides glycosyl and the aglycon-the OH group makes it fat-soluble low, is difficult for directly through hemato encephalic barrier.After it entered in the body, the hydrolysis of Gastrodine elder generation generated gastrodia elata genin, and then gastrodia elata genin sees through hemato encephalic barrier, is attached to benzene phenodiazine acceptor, strengthens the avidity of gaba receptor, and then performance maincenter retarding effect, therefore had the slow shortcoming of onset.
Summary of the invention
The inventor finds after deliberation by hydroxy esterification on the Gastrodine phenyl ring being obtained gastrodin derivative 4-(acetyl-o-methyl) phenylpyran glucoside, then improved the fat-soluble of Gastrodine, the gained gastrodin derivative is easy to see through hemato encephalic barrier, and activity is not less than Gastrodine.
Therefore the present invention relates to the gastrodin derivative of formula I,
Wherein,
Expression β type key.
The invention still further relates to the method for preparation formula I gastrodin derivative, it comprises:
With the following formula Gastrodine
With phenyl aldehyde (PhCHO) at concentrated hydrochloric acid and/or ZnCl
2There is reaction down, production 2 compounds
With formula 2 compounds and acetic acid reaction, get formula I gastrodin derivative
The invention still further relates to a kind of pharmaceutical composition, it comprises formula I gastrodin derivative and pharmaceutical excipient.
The invention still further relates to formula I compound purposes in the preparation medicine.
According to the present invention, formula I gastrodin derivative of the present invention can prepare shown in following reaction scheme:
Reaction scheme
In the reaction scheme, get concentrated hydrochloric acid 10～30ml in the above, add phenyl aldehyde 3～6g, mechanical stirring.Get Gastrodine 3～5g, less water dissolving back slowly adds in the three-necked bottle with feed hopper.Behind the stirring reaction 5～9 hours, use petroleum ether extraction reaction solution 3 times, collect organic phase, after the solvent evaporated, add 5% acetic acid, regulate pH value to 2～5, be heated to 60 ℃ then and kept 3～8 hours.With petroleum ether extraction reaction solution 3 times, collect organic phase, reclaim solvent promptly, yield is 45～65%.The product that obtains determines that through ultraviolet, infrared, mass spectrum, nuclear magnetic resonance measuring this product is: 4-(acetyl-o-methyl) phenylpyran glucoside, and determination data following (corresponding charts is seen accompanying drawing 1～7):
Ultraviolet spectrum data: UV λ
Max MeOH: 222.6nm (∈ 10369), 202.4nm (∈ 7424);
Ir data: IR 3431cm
-1(hydroxyl), 1738cm
-1(ester group), 1615cm
-1, 1575cm
-1, 1514cm
-1, 1456cm
-1(phenyl ring);
Mass-spectrometric data: FAB
+MS (m/z, rel%): 482 (M+MNBA+1,9), 329 (M+1,19), 328 (M, 30), 284 (M, 16), 269 (M-HOAc+1,100), 166 (M-Glc, 23);
Nucleus magnetic resonance (HMQC) data: 130.5---7.29; 117.3---7.04; 101.9---4.95; 66.1---5.00; 62.7---3.86,3.70;
Nucleus magnetic resonance (HMBC) data: 170.8---5.00,2.00; 158.7---7.29,7.04,4.95; 131.0---7.29,7.04,5.00; 130.5---7.04; 117.3---7.29; 66.1---7.29;
Description of drawings
Fig. 1 is the UV spectrum of formula I compound;
Fig. 2 is the infrared spectra of formula I compound;
Fig. 3 is the mass spectrum of formula I compound;
Fig. 4 is the nucleus magnetic resonance of formula I compound
1The H spectrum;
Fig. 5 is the nucleus magnetic resonance of formula I compound
13The C spectrum;
Fig. 6 is the nucleus magnetic resonance HMBC spectrum of formula I compound;
Fig. 7 is the nucleus magnetic resonance HMQC spectrum of formula I compound;
According to the present invention, in the preparation present composition, usually 4-(acetyl-o-methyl) phenylpyran glucoside is mixed with pharmaceutic adjuvant, or dilute with medicinal auxiliary material, or be encapsulated in the pharmaceutic adjuvant. Described auxiliary material can be solid, semisolid or the liquid that 4-(acetyl-o-methyl) phenylpyran glucoside is played carrier, excipient or medium effect. Suitable excipient example comprises lactose, dextrose, sucrose, D-sorbite, mannitol, starch, Arabic gum, calcium phosphate, alginates, bright limb, syrup, methylcellulose, methyl hydroxybenzoate and propyl ester, talcum, dolomol or oil. If necessary, the present composition can be made into slowly-releasing or controlled release preparation, so as to give to provide behind the patient activating component fast, release that continue or that postpone.
According to method of administration, but the above-mentioned composition preparation becomes tablet, capsule or suspension for oral application, and makes injection solution etc. and use for non-enteron aisle, or makes suppository.
Embodiment
The following examples are used for further describing the present invention, but it does not mean that any limitation of the invention.
Synthesizing of 4-(acetyl-o-methyl) phenylpyran glucoside
In the 100ml three-necked bottle, add concentrated hydrochloric acid 20ml, add phenyl aldehyde 4g, mechanical stirring.Get Gastrodine 3g, less water dissolving back slowly adds in the three-necked bottle with feed hopper.Behind the stirring reaction 6 hours, use the petroleum ether extraction reaction solution, collect organic phase, after the solvent evaporated, add 5% acetic acid, regulate pH value to 3, be heated to 60 ℃ then and kept 3 hours.Use the petroleum ether extraction reaction solution, collect organic phase, solvent evaporated goes up the fractionation that separator column carries out isomer subsequently and promptly gets title compound, shown in its appraising datum reaction scheme provides in illustrating as described above the data and/or accompanying drawing 1-7.
Every tablet preparation that contains 20mg4-(acetyl-o-methyl) phenylpyran glucoside is as follows:
4-(acetyl-o-methyl) phenylpyran glucoside 20mg
Starch 210mg
Microcrystalline Cellulose 40mg
This pyrrolidone of polyethylene (10% aqueous solution fine horse) is an amount of
Sodium starch glycolate 14mg
Magnesium Stearate 3mg
Amount to 300mg
With 4-(acetyl-o-methyl) phenylpyran glucoside, starch and Mierocrystalline cellulose thorough mixing.This sneezes alkane ketone solution with the powder mixes that obtains and sieve with polyethylene, the particle drying that makes and after sieve.Sodium starch glycolate and Magnesium Stearate are added in this particle, mix back compressing tablet on tabletting machine, get every heavy 300mg,
The capsule that every capsule contains 20mg4-(acetyl-o-methyl) phenylpyran glucoside is prepared as follows
4-(acetyl-o-methyl) phenylpyran glucoside 20mg
Dry starch 278mg
Magnesium Stearate 2mg
Amount to 300mg
4-(acetyl-o-methyl) phenylpyran glucoside, starch and Magnesium Stearate are sieved, and be packed in the hard gelatin capsule with the amount of 300mg.
Every injection liquid that contains 10mg4-(acetyl-o-methyl) phenylpyran glucoside is prepared as follows
4-(acetyl-o-methyl) phenylpyran glucoside 10g
Ethanol 80g
Sodium-chlor 9g
Water for injection adds to 1000ml
Get 4-(acetyl-o-methyl) phenylpyran glucoside 10g, add the ethanol stirring and dissolving, add sodium-chlor 9g, add the injection water to 800ml, 9g sodium-chlor, regulating the pH value is 6.0～6.5; The needle-use activated carbon of adding 0.1% in above-mentioned solution, absorption, decarbonization filtering; Add the injection water to 1000ml; Extremely clear and bright with filtering with microporous membrane, embedding; 100 ℃ of moist heat sterilizations 20 minutes, cooling is up to the standards, promptly rapidly.
Every freeze-dried powder that contains 10mg4-(acetyl-o-methyl) phenylpyran glucoside is prepared as follows
4-(acetyl-o-methyl) phenylpyran glucoside 10g
Ethanol 80g
Sodium-chlor 9g
N.F,USP MANNITOL is an amount of
Water for injection adds to 4000ml
In workshop more than 100 grades, get 4-(acetyl-o-methyl) phenylpyran glucoside 10g, add the ethanol stirring and dissolving, add sodium-chlor 9g, N.F,USP MANNITOL is an amount of, adds the injection water to 800ml, and regulating the pH value is 6.0～6.5, filters; Add the injection water to 4000ml; To clear and bright, be distributed into every 4.0ml with filtering with microporous membrane, lyophilize is covered plug, is rolled lid, and the lyophilize powder injection that promptly gets every 10mg (effective constituent) is up to the standards, promptly.
The pharmacological toxicology test:
One, acute toxicity test
Mouse male and female half and half, body weight 18-20g.
1. gastric infusion: do toxicity prerun with mice group, irritate stomach for 5.0% 4-(acetyl-o-methyl) phenylpyran glucoside ethanolic soln, dosage was observed 7 days after the administration by 1250-5000mg/kg, did not see and poisoned and the phenomena of mortality.
2. intravenous injection: mice group is made toxicity test, and the 4-with 5.0% (acetyl-o-methyl) phenylpyran glucoside ethanolic soln is done tail vein injection, and dosage was observed 7 days after the administration by 2500-5000mg/kg, does not see and poisons and death.
Two, pharmacological evaluation
1. to the sedative effect of mouse
Press the SchlaginweitShi method (shake cage graphical method) of Hu Chongjia improvement, it is a collection of to get small white mouse, body weight 18-20g, male and female half and half, first subcutaneous injection caffeine sodium benzoate 50mg/kg, its activity is increased, inject 4-(acetyl-o-methyl) phenylpyran glucoside after 30 minutes again, control group subcutaneous injection physiological saline, sodium phenobarbital, be 180 minutes observing time, being less than 120 minutes with activity is index, the results are shown in Table 1.The result shows that 4-(acetyl-o-methyl) phenylpyran glucoside has sedative effect, and the sedative effect curative effect is dosage correlation.
Table 1.4-(acetyl-o-methyl) phenylpyran glucoside
Sedative effect to small white mouse
| Group | Number of animals (only) | Dosage mg/kg | Observing time (minute) | The mean activity time (minute) | Calm index * |
| Normal control group (physiological saline) | 10 | 50 | 180 | 145.3 | --- |
| Positive controls (sodium phenobarbital) | 10 | 50 | 180 | 80.1 | 1.81 |
| 4-(acetyl-o-methyl) phenylpyran glucoside | 10 | 10 | 180 | 63.8 | 2.28 |
| Dosage group in 4-(acetyl-o-methyl) the | 10 | 30 | 180 | 44.2 | 3.29 |
| 4-(acetyl-o-methyl) phenylpyran glucoside |
10 | 50 | 180 | 26.7 | 5.44 |
*Calm index=physiological saline group mean activity time (minute)/the test group mean activity time (minute)
2. anticonvulsion experiment
Selection causes frightened agent Yetrazol and central nervous system stimulants Nikethamide, causes the mice convulsion model, observes the anticonvulsant action of 4-(acetyl-o-methyl) phenylpyran glucoside.Wherein the Yetrazol method is the classical pharmacological method of anticonvulsion test.Test-results sees Table 2, and the result shows that three dosage groups of 4-(acetyl-o-methyl) phenylpyran glucoside produce the number of animals and the comparison of fainting from fear, there was no significant difference (P＞0.05) to the central stimulant Yetrazol.4-(acetyl-o-methyl) phenylpyran glucoside high dose group dead mouse number and normal control group relatively have significant difference (P＜0.05).Show that 4-(acetyl-o-methyl) phenylpyran glucoside liquid can reduce the mortality ratio of fainting from fear due to the Yetrazol.
Table 2.4-(acetyl-o-methyl) phenylpyran glucoside
Yetrazol is caused the influence of mice convulsion
| Group | Number of animals (only) | Dosage mg/kg | Convulsions number of animals (only) | Dead animal number (only) |
| Normal control group (sodium chloride injection) | 10 | Equal-volume | 9 | 6 |
| Positive controls (diazepam) | 10 | 1.3 | 0 | 0 * |
| 4-(acetyl-o-methyl) phenylpyran glucoside | 10 | 133 | 8 | 1 * |
| Dosage group in 4-(acetyl-o-methyl) the | 10 | 66.7 | 8 | 2 |
| 4-(acetyl-o-methyl) phenylpyran glucoside | 10 | 33.4 | 8 | 3 |
Chi square test and normal control group are relatively
*P＜0.05
The anti-Nikethamide of 4-(acetyl-o-methyl) phenylpyran glucoside causes the mice convulsion test.Test-results sees Table 3, and the result shows in 4-(acetyl-o-methyl) the phenylpyran glucoside, low dosage can prolong central stimulant Nikethamide mice convulsion latent period, with the normal control group relatively, significant difference (P＜0.05) is arranged.4-(acetyl-o-methyl) phenylpyran glucoside does not have influence (P＞0.05) to the death time of convulsions mouse.Show that 4-(acetyl-o-methyl) phenylpyran glucoside has certain anticonvulsant action.
Table 3.4-(acetyl-o-methyl) phenylpyran glucoside
To the influence X ± SD of Nikethamide to mice convulsion
| Group | Number of animals (only) | Dosage mg/kg | Faint from fear latent period (s) | Death time (s) |
| Normal control group (sodium chloride injection) | 12 | Equal-volume | 75.9±10.2 | 1221.6±598.6 |
| Positive controls (diazepam) | 12 | 1.3 | 100.6±28.0 * | 1800.0±1.0 ** |
| 4-(acetyl-o-methyl) phenylpyran glucoside high dose group | 12 | 133 | 81.3±19.6 | 1245.1±521.4 |
| Dosage group in 4-(acetyl-o-methyl) the phenylpyran glucoside | 12 | 66.7 | 94.3±25.0 * | 1261.0±505.7 |
| 4-(acetyl-o-methyl) phenylpyran glucoside low dose group | 12 | 33.4 | 87.7±14.6 * | 1046.3±532.5 |
Compare with the normal group control group
*P＜0.05,
*P＜0.01.
4-(acetyl-o-methyl) phenylpyran glucoside high dose group can reduce the mortality ratio of fainting from fear due to the Yetrazol.In 4-(acetyl-o-methyl) the phenylpyran glucoside, low dosage can prolong central stimulant Nikethamide mice convulsion latent period, but the death time of convulsions mouse do not had influence.Show that 4-(acetyl-o-methyl) phenylpyran glucoside has certain anticonvulsant action.
3. analgesic activity
Select writhing method and two kinds of test methods of hot plate method to observe 4-(acetyl-o-methyl) phenylpyran glucoside respectively to chemical factor and the pain caused influence of physical factor, experiment each treated animal on the same day is by setting dosage administered intramuscular 1 time.
The writhing method test-results sees Table 4, the result shows, the body number of times of turning round of 4-(acetyl-o-methyl) phenylpyran glucoside height, middle dosage mouse reduces, compare with the normal control group, 4-(acetyl-o-methyl) phenylpyran glucoside high dosage has significant difference, shows that 4-(acetyl-o-methyl) phenylpyran glucoside has the analgesic activity of anti-glacial acetic acid to mouse.
Table 4. pair mouse acetic acid causes influence (writhing method) x ± SD that pain is turned round the body number of times
| Group | Number of animals (only) | Dosage mg/kg | The mouse writhing number of times/time |
| Normal control group (sodium chloride injection) | 12 | Equal-volume | 49.17±11.16 |
| Positive controls (atropine sulfate injection) | 12 | 0.05 | 30.42±9.26 ** |
| 4-(acetyl-o-methyl) phenylpyran glucoside high dose group | 12 | 133 | 37.67±10.47 * |
| Dosage group in 4-(acetyl-o-methyl) the phenylpyran glucoside | 12 | 66.7 | 41.25±12.26 |
| 4-(acetyl-o-methyl) phenylpyran glucoside low dose group | 12 | 33.4 | 46.33±12.22 |
Compare with the normal control group
*P＜0.05,
*P＜0.01.
The hot plate method test-results sees Table 5, the result shows, 4-(acetyl-o-methyl) high, medium and low dosage of phenylpyran glucoside and normal control group are relatively, significant difference is all arranged, each dosage group all continues for some time, and shows that 4-(acetyl-o-methyl) phenylpyran glucoside has certain analgesic activity.
Table 5.4-(acetyl-o-methyl) phenylpyran glucoside
Influence (hot plate method) x ± SD to mouse hot plate threshold of pain
| Group | Number of animals (only) | Dosage mg/kg | The preceding threshold of pain/the s of administration | The different time threshold of pain/s after the administration | |
| 30min | 60min | ||||
| Normal control group (sodium chloride injection) | 12 | Equal-volume | 23.67±3.39 | 22.75±2.18 | 21.50±3.0 9 |
| Positive controls | 12 | 50 | 24.25±3.11 | 31.33±4.66 ** | 28.92±5.32 |
| (Compound Amidopyrin Injection) | ** | ||||
| 4-(acetyl-o-methyl) phenylpyran glucoside high dose group | 12 | 133 | 24.25±3.74 | 26.67±3.70 ** | 27.75±6.12 ** |
| Dosage group in 4-(acetyl-o-methyl) the phenylpyran glucoside | 12 | 66.7 | 23.67±3.89 | 27.25±3.77 ** | 29.33±5.18 ** |
| 4-(acetyl-o-methyl) phenylpyran glucoside low dose group | 12 | 33.4 | 23.92±4.74 | 24.58±4.01 | 24.83±2.86 * |
Compare with the normal control group
*P＜0.05,
*P＜0.01.
4-(acetyl-o-methyl) phenylpyran glucoside high dose group can reduce the mouse writhing number of times due to the acetic acid, three dosage groups all can improve the threshold of pain of mouse, and have certain ageing, the mouse pain effect that has anti-chemical factor and physical factor to cause shows that 4-(acetyl-o-methyl) phenylpyran glucoside has certain analgesic activity.
As mentioned above, material of the present invention has the central nervous system activity.Material of the present invention is active to gaba receptor.Be used for the treatment of neurological conditions, for example dizzy: Meniere, medicine toxic vertigo, traumatic vertigo, sudden deafness, vestibular neuronitis, vertebro-basilar artery insufficiency etc.; Neurodynia: trigeminal neuralgia, sciatica, neuralgia of greater occipital nerve etc.; Headache: vascular headache, migraine, neurasthenia and the god syndrome etc. that declines; Also can be used for disease and presenile dementia and dyssomniases such as assisting therapy epilepsy.
Material of the present invention is effective in a very wide dosage range.Actual dosage depends on various factors, for example the disease of desire treatment, mammiferous kind and size to be treated.
Claims (10)
1. the gastrodin derivative of general formula formula I:
Wherein,
2. according to the described derivative of claim 1, wherein R combines with glycosyl with β type key.
3. pharmaceutical composition, it comprises the gastrodin derivative and the pharmaceutical excipient of claim 1 or 2.
4. claim 1 or 2 gastrodin derivative purposes in the preparation medicine.
5. the gastrodin derivative preparation method of claim 1, it comprises:
With the following formula Gastrodine
With phenyl aldehyde (PhCHO) at concentrated hydrochloric acid and/or ZnCl
2There is reaction down, production 2 compounds
With formula 2 compounds and acetic acid reaction, get formula I gastrodin derivative
6. substances preparation method according to claim 5 is characterized in that reaction raw materials is selected from phenyl aldehyde, formaldehyde, and acid is selected from the concentrated hydrochloric acid or the vitriol oil, and selectivity adds zinc chloride as catalyzer, and the reaction times is 6 hours.
7. preparation method according to claim 5, the diluted acid that wherein is used to regulate pH is selected from 5% acetic acid and 10% acetic acid, and pH is 3, and should be not less than 3 hours heat-up time, and selectivity adds bariumchloride and handles.
8. the described purposes of claim 4, wherein said medicine is the medicine that is used for the treatment of senile cardiovascular and cerebrovascular and cranial nerve diseases.
9. according to the described composition of claim 3, it is oral preparations or injection form.
10. the composition of claim 9, wherein oral preparations is tablet or capsule, injection is injection liquid or powder injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100569362A CN100410265C (en) | 2004-08-20 | 2004-08-20 | Gastrodine derivative, its preparation method, pharmaceutical composition and uses |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100569362A CN100410265C (en) | 2004-08-20 | 2004-08-20 | Gastrodine derivative, its preparation method, pharmaceutical composition and uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1737007A true CN1737007A (en) | 2006-02-22 |
| CN100410265C CN100410265C (en) | 2008-08-13 |
Family
ID=36079977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100569362A Expired - Lifetime CN100410265C (en) | 2004-08-20 | 2004-08-20 | Gastrodine derivative, its preparation method, pharmaceutical composition and uses |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100410265C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104231013A (en) * | 2014-08-26 | 2014-12-24 | 上海现代哈森（商丘）药业有限公司 | Gastrodin ferulate compound and preparation method and application of gastrodin ferulate compound |
| CN104804051A (en) * | 2014-01-25 | 2015-07-29 | 昆明制药集团股份有限公司 | Acetagastrodin derivative, preparation method, preparation, and applications thereof |
| CN110028534A (en) * | 2019-05-17 | 2019-07-19 | 昆药集团股份有限公司 | A kind of Rhizoma Gastrodiae chlorins compound, preparation method and application |
| CN112851725A (en) * | 2019-11-12 | 2021-05-28 | 中国海洋大学 | Gastrodin derivative and preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1428345A (en) * | 2002-11-22 | 2003-07-09 | 云大科技股份有限公司 | Chemical synthesis process for preparing gastrodin and its analogous henolic glycoside formula (I) |
-
2004
- 2004-08-20 CN CNB2004100569362A patent/CN100410265C/en not_active Expired - Lifetime
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104804051A (en) * | 2014-01-25 | 2015-07-29 | 昆明制药集团股份有限公司 | Acetagastrodin derivative, preparation method, preparation, and applications thereof |
| CN104804051B (en) * | 2014-01-25 | 2017-12-12 | 昆药集团股份有限公司 | A kind of Acegastrodine derivative and preparation method thereof, preparation and application |
| CN104231013A (en) * | 2014-08-26 | 2014-12-24 | 上海现代哈森（商丘）药业有限公司 | Gastrodin ferulate compound and preparation method and application of gastrodin ferulate compound |
| CN110028534A (en) * | 2019-05-17 | 2019-07-19 | 昆药集团股份有限公司 | A kind of Rhizoma Gastrodiae chlorins compound, preparation method and application |
| CN110028534B (en) * | 2019-05-17 | 2020-11-17 | 昆药集团股份有限公司 | Novel compound in gastrodin injection and preparation method and application thereof |
| CN112851725A (en) * | 2019-11-12 | 2021-05-28 | 中国海洋大学 | Gastrodin derivative and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100410265C (en) | 2008-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1224383C (en) | Blood sugar reducing compound | |
| CN1737007A (en) | Gastrodine derivative, its preparation method, pharmaceutical composition and uses | |
| CN1475272A (en) | Sydroxy carthamin A and its preparation method and use | |
| CN1698871A (en) | Health product for assisting blood sugar-decreasing function and its preparation method | |
| CN1199682C (en) | Medicine composition for treating depression and its prepn | |
| CN1857622A (en) | Medicine composition and preparation containing effective components of gastrodia tuber and Chuanxiong rhizome | |
| CN1314397C (en) | Effective site extract of lotus plumule and its usage | |
| CN1303098C (en) | Pseudo portulaca oleracea saponin compound, total sapon in and its application in medicine | |
| CN1300175C (en) | Medicinal polysaccharide component of spinulate hedgehog fungus, its prepn and medicinal composition | |
| CN1417218A (en) | Kaempferol derivative and its medicinal use | |
| CN1506090A (en) | Rheum emodi wall extract and medicine composition with the extract as active component | |
| CN1552425A (en) | Water snowflake extract, preparation and use thereof | |
| CN1733054A (en) | Dogwood fruit extract and its preparation process | |
| CN1634461A (en) | Honey suckle and baikal skullcap root freeze dried injection and its preparing method | |
| CN1915994A (en) | Indole group alkaloid of sector Gouyahua, and application for preparing drug-breaking medicine | |
| CN1259099C (en) | Prepared traditional Chinese drug Liangfu drop pills for treating epigastric pain | |
| CN1763069A (en) | Gen-seng saponin Rg2 preparation method, its pharmaceutical composition and uses in pharmacy | |
| CN1279931C (en) | Medicine for treating primary and secondary headache | |
| CN1313132C (en) | Medicine composition for treating coronary heart disease and its prepn process | |
| CN1884246A (en) | Method for extracting diaryl heptane compounds from galangas | |
| CN1562285A (en) | Combination of active constituent of Chinese traditional medicine for curing cardiovascular and cerebrovascular diseases and preparation method | |
| CN1718578A (en) | Lerivisiticum extract, its preparation method and medicine containing said extract | |
| CN1287790C (en) | Kusnezoff monkshood root methyl element microcapsule and its production method | |
| CN1608628A (en) | Application of sweet leaf glycoside R1 and its derivatives as drugs for preventing and treating neurodegenerative diseases | |
| CN1201775C (en) | Medicine for treating insomnia-sleeping particle and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Yunnan Kingtide Notoginseng Industry Co.,Ltd. Assignor: KUNMING PHARMACEUTICAL Corp. Contract fulfillment period: 2009.8.31 to 2024.8.19 Contract record no.: 2009530000039 Denomination of invention: Gastrodine derivative, its preparation method, pharmaceutical composition and uses Granted publication date: 20080813 License type: Exclusive license Record date: 20091012 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.8.31 TO 2024.8.19; CHANGE OF CONTRACT Name of requester: YUNNAN JINTAIDE NOTOGINSENG INDUSTRY CO., LTD. Effective date: 20091012 |
|
| C56 | Change in the name or address of the patentee |
Owner name: KPC CO., LTD. Free format text: FORMER NAME: KUNMING PHARMACEUTICAL INDUSTRY GROUP CORP., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 650106 Kunming science and Technology Industrial Development Zone, Yunnan Province Road No. 166 Patentee after: KPC PHARMACEUTICALS, Inc. Address before: 650106 No. 166, medical Road, Kunming hi tech Industrial Development Zone, Yunnan, China Patentee before: KUNMING PHARMACEUTICAL Corp. |
|
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: KUNSHAN PHARMACEUTICAL GROUP XUESHUANTONG PHARMACEUTICAL Co.,Ltd. Assignor: KPC PHARMACEUTICALS, Inc. Contract record no.: 2009530000039 Date of cancellation: 20161114 |
|
| EM01 | Change of recordation of patent licensing contract |
Change date: 20161111 Contract record no.: 2009530000039 Assignee after: KUNSHAN PHARMACEUTICAL GROUP XUESHUANTONG PHARMACEUTICAL Co.,Ltd. Assignee before: Yunnan Kingtide Notoginseng Industry Co.,Ltd. Change date: 20161111 Contract record no.: 2009530000039 Assignor after: KPC PHARMACEUTICALS, Inc. Assignor before: KUNMING PHARMACEUTICAL Corp. |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| CX01 | Expiry of patent term |
Granted publication date: 20080813 |
|
| CX01 | Expiry of patent term |